Retrophin, Inc. (RTRX) was a big mover last session, as the company saw its shares surge ahead 18% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company as the stock is now down about 24.8% in the past one-month time frame.
In the last 30 days, the company witnessed 1 downward estimate revision and the Zacks Consensus Estimate of a loss widened, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent high can last.
Retrophin currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Other better-ranked players in the healthcare industry include Myriad Genetics Inc. (MYGN), ANI Pharmaceuticals, Inc. (ANIP) and Aastrom Biosciences, Inc. (ASTM) all carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment